TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients
Biomarker Research volume 8, Article number: 10 (2020)
Primary testicular lymphoma (PTL), often appearing as focal masses in the scrotum and epididymides, is the most frequent testicular tumor in aged men. Although MYD88 and CD79B mutations were the most common genetic alterations observed, the gene mutation landscape of PTL remains poorly defined. In this study, we identified 1326 mutations involving 311 genes or regions in 90 PTL patients through next-generation sequencing (NGS). PTL patients with the TBL1XR1 mutation, irrespective of treatment therapy, had an inferior overall survival (OS) than TBL1XR1 WT (wild type) patients (p = 0.045). Moreover, patients with this mutation, treated with a CHOP regimen (CTX 750 mg/m2 iv, d1,8 ADM 50 mg/m2 iv, d1 VCR 1.4 mg/m2 iv, d1 PDN 100 mg/m2 po d1–5), had a poorer OS (p = 0.019). In addition, such patients were prone to have a more intensive infiltration of tumors (p = 0.025, x2 = 4.890). Thus, we speculated that patients with a TBL1XR1 mutation have poorer prognosis, partly due to greater invasion and infiltration of tumors. Our results suggest that the TBL1XR1 mutation can be used as an indicator to predict the prognosis of PTL and can be employed as a promising new target for treatment of PTL in the future.
To the editor:
Primary testicular lymphoma (PTL) is a rare, clinically aggressive type of extra nodal lymphoma . Approximately 80–98% of PTL cases are diagnosed as diffuse large B-cell lymphoma (DLBCL), a common heterogeneous type of non-Hodgkin’s lymphoma (NHL) . PTL features a high risk of relapse in the central nervous system (CNS) and contralateral testis, directly leading to a poor outcome in the patients . In recent years, the addition of radiotherapy, full-course chemotherapy and CNS-directed prophylaxis and rituximab have greatly improved the prognosis of DLBCL patients; however, the prognosis for PTL remains poor . Previous studies reported that B symptoms, advanced Ann Arbor stage (III/IV), and extra nodal involvement are poor prognostic markers for PTL . MYD88 and CD79B mutations are frequently observed in PTL, but no prognostic impact was observed . The gene mutation landscape and the prognosis of PTL remain poorly defined. In addition, information on different mutations in PTL is not available.
In our study, we used NGS to clarify the mutation landscape of PTL in 90 patients, who attended the First Affiliated Hospital of Soochow University and the First Affiliated Hospital of Nantong University between January 2007 and July 2018. This study was approved by the Ethics committee of the First Affiliated Hospital of Soochow University in accordance to the Declaration of Helsinki. Sixty-six patients (73%) received an anthracyline-based chemotherapy, usually CHOP regimen. Twenty-four patients (27%) were simultaneously treated with rituximab. The median chemotherapy course was six courses. Twelve patients received irradiation aimed at the contralateral testis, and no patient received head irradiation. OS was estimated using the Kaplan-Meier method. The two-sided level of significance was p < 0.05. Statistical analyses were performed using SPSS 23.0. The follow-up was updated on August 31, 2019, with a median follow-up time of 36 (1–120) months. Fourteen patients (15.5%) were lost to follow-up (Supplementary Table 1 and 2).
Patients’DNA was extracted from paraffin-embedded tissues in accordance to the manufacturer’s protocol and were sequenced on an Illumina Hiseq 2000 instrument using a targeted panel covering 446 genes (Table 1 in Supplementary Appendix). We identified 1326 mutations involving 311 genes or regions in 90 PTL patients. MYD88 mutations were the most frequently observed mutation, occurring in 75.6% (68/90) patients. Other commonly mutated genes were PIM1 (71.1%), TBL1XR1 (37.8%), KMT2D (37.8%) and KMT2C (34.4%) (Fig. 1a, supplementary information is given in Table 3). There was a positive correlation between TBL1XR1 and PIM1/BTG2 mutations (r = 0.244 and r = 0.247, respectively) (Table 1). PTL patients with TBL1XR1 mutation, irrespective of treatment therapy, had an inferior OS than TBL1XR1 WT patients (p = 0.045, HR 1.854, 95%CI 1.004–3.442) (Fig. 1b). Moreover, patients carrying this mutation, treated with CHOP regimen, also had poorer OS (p = 0.019, HR 2.378, 95%CI 1.121–5.045) (Fig. 1c).
TBL1XR1, also known as TBLR1, is an evolutionarily conserved protein that has high structural and functional similarities. It plays an important role in activation of multiple intracellular signaling pathways, such as Wnt-β-catenin, NF-κB, and Notch signaling pathways . Dysregulation of TBL1XR1 has been observed in lots of neoplastic conditions . TBL1XR1 is preferentially expressed in human CD34 + CD38- cells and vital for stem cell balancing. In B-cell acute lymphoblastic leukemia, function loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin, resulting in glucocorticoid resistance .
In addition, patients with TBL1XR1 mutation were prone to have more intensive infiltration of tumors (p = 0.025, x2 = 4.890). This finding is consistent with a previous study, which reported that abnormal regulation of TBL1XR1 is associated with advanced tumor stage, metastasis, and poor prognosis in most solid tumors . Patients with tumor infiltration had poorer outcomes, and there was a statistical difference between TBL1XR1 mutation and WT groups (p = 0.002, HR 2.568, 95%CI 1.382–4.772) (Fig. 1d). OS of patients with TBL1XR1 mutation treated with CHOP regimen was 11.5% whereas OS of patients with TBL1XR1 mutation treated with R-CHOP regimen was 100% (6/6). Thus, we speculate that rituximab may improve the prognosis of patients with TBL1XR1 mutations, but this needs to be further studied by more patients.
In conclusion, we found that TBL1XR1 is commonly mutated in PTL. Patients with TBL1XR1 mutations have lower OS, partly due to greater invasion and infiltration of tumors. Therefore, TBL1XR1 mutation can be used as an indicator to predict the prognosis of PTL and a promising new target for treatment of PTL in future.
Availability of data and materials
All data obtained and/or analyzed during the current study were available from the corresponding authors in a reasonable request.
Primary testicular lymphoma
Diffuse large B-cell lymphoma
Central nervous system
Transducin (beta)-like 1X related protein 1
CTX, ADM, VCR, PDN
Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123:486–93.
Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the international PTL consortium. Leukemia. 2016;30:361–72.
Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE, Egan KS, Martenson JA, Burgart LJ, Inwards DJ. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88:154–61.
Zhou BC, Ye X, Zhu L, Zhu J, Li L, Zhu M, Yang X, Zheng Y, Huang X, et al. Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China. Oncotarget. 2017;8:112384–9.
Ma RZ, Tian L, Tao LY, He HY, Li M, Lu M, Ma LL, Jiang H, Lu J. The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience. Asian J Androl. 2018;20:615–20.
Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, Yamamoto T, Iizuka J, Tanabe K, Shibata N, et al. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. Pathol Int. 2015;65:528–35.
Chen SP, Yang Q, Wang CJ, Zhang LJ, Fang Y, Lei FY, Wu S, Song LB, Guo X, Guo L. Transducin beta-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in nasopharyngeal carcinoma via activation of NF-kappaB pathway. Mol Cancer. 2014;13:195.
Wang J, Ou J, Guo Y, Dai T, Li X, Liu J, Xia M, Liu L, He M. TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer. Br J Cancer. 2014;111:112–24.
Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18:5203–11.
Li JY, Daniels G, Wang J, Zhang X. TBL1XR1 in physiological and pathological states. Am J Clin Exp Urol. 2015;3:13–23.
This study was supported by grant from the National Key R&D Program of China (2019YFA0111000), the National Natural Science Foundation of China (81570139, 81600116, 81600114, 81700140, 81970142, 81900130, 81970136), the Natural Science Foundation of the Jiangsu Higher Education Institution of China (18KJA320005), the Natural Science Foundation of Jiangsu Province (BK20190180), China Postdoctoral Science Foundation (2018 M632372), and the priority academic program development of Jiangsu Higher Education Institution.
Ethics approval and consent to participate
Sample collections were approved by Ethnics Committee of the First Affiliated Hospital of Soochow University. The informed consent was obtained from patients or their guardians, as appropriate.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Table S1. 446 known or putative mutational gene targets in hematologic malignancies detected by the next generation sequencing. Table S2. Characteristics of 90 PTL patients. Table S3. Mutated characteristics of 34 TBL1XR1 mutation PTL patients
About this article
Cite this article
Wang, X., Xu, X., Cai, W. et al. TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients. Biomark Res 8, 10 (2020). https://doi.org/10.1186/s40364-020-00189-1